Home › Compare › TMPPF vs ABBV
TMPPF yields 4000.00% · ABBV yields 3.06%● Live data
📍 TMPPF pulled ahead of the other in Year 1
Combined, TMPPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TMPPF + ABBV for your $10,000?
Times China Holdings Limited, an investment holding company, operates as a property developer in the People's Republic of China. The company operates through Property Development, Urban Redevelopment Business, and Property Leasing segments. The Property Development segment develops and sells residential and commercial properties. The Urban Redevelopment Business segment is involved in the sale of land held for development and other related activities. The Property Leasing segment engages in the development, leasing, and sub-leasing of commercial properties owned by the company or independent third parties. The company also provides money lending and consulting management services. As of 31 December 2021, it had total land reserves of approximately 19.9 million sq.m. The company was formerly known as Times Property (Holdings) Co., Limited and changed its name to Times China Holdings Limited in February 2018. Times China Holdings Limited was founded in 1999 and is headquartered in Guangzhou, the People's Republic of China.
Full TMPPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.